Clinical Trials Logo

Liver Steatosis clinical trials

View clinical trials related to Liver Steatosis.

Filter by:

NCT ID: NCT06446908 Not yet recruiting - Liver Steatosis Clinical Trials

Acceptability and Feasibility of a New Approach to Engage Patients With Steatotic Liver Disease in Physical Activity

Start date: August 1, 2024
Phase: N/A
Study type: Interventional

Steatosis is the building of fat in the liver. Steatotic liver disease (SLD) regroups MASLD (metabolic dysfunction-associated steatotic liver disease) and MASH (metabolic dysfunction-associated steatohepatitis) i.e. MASLD with inflammation. An estimated 30% of the population worldwide has MASLD and 5% of Canadians have MASH. MASH is a leading cause of liver transplantation in Canada. There is no cure for SLD, and the treatment relies on diet, weight loss, and physical activity (PA). Is a counselling intervention to help patients progressively engage in more PA a feasible and acceptable approach? Objectives. This proposal has three primary objectives: 1) To assess the feasibility of our PA counselling intervention (to be delivered online) with SLD patients; 2) To evaluate the acceptability of our intervention; 3) To evaluate the feasibility of the study methods/procedures. Methodology. This study is an open-label, mono-centred, single-case experimental design with multiple base levels. The study will comprise 3 phases, alternating periods of observation (A) and 1 period of counselling (B) with an A1-B-A2 design. PA will be assessed continuously using an accelerometer for 7 to 14 days per (A) phase. During phase (B), participants will receive the intervention, i.e. 6 x 45-minute, real-time, face-to-face, virtual sessions with a PA counsellor. Based on past studies, our sample size will be 12 participants. They will be recruited through the hepatology clinic at Hôpital Montfort. The primary outcomes of the project are to evaluate the feasibility and acceptability of the trial and intervention. The secondary outcomes are Daily PA time and biological/imaging data evolution

NCT ID: NCT06102980 Not yet recruiting - Liver Steatosis Clinical Trials

Endoscopic Ultrasound Shear Wave vs Transient Elastography for Liver Steatosis: The RUMIPAMBA Trial

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

Currently, there is no description of the contribution of the endoscopic ultrasound (EUS)-guided shear wave elastography (SWE) when describing liver steatosis in patients with suspicion of metabolic dysfunction-associated steatotic liver disease (MASLD). Similar research have been published but using vibration-controlled transient elastography (VCTE), recommended mainly due to its lower cost and less invasiveness. However, VCTE is limited to the anatomical proportions of the patient's body, and cannot assess the right hepatic lobe with less reliability, in opposition to the EUS-SWE.

NCT ID: NCT05946148 Completed - Clinical trials for Non-Alcoholic Fatty Liver Disease

Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)

NAMELS-18
Start date: June 1, 2018
Phase:
Study type: Observational

The goal of this clinical study is to compare the therapeutic effect of Dulaglutide and Empagliflozin in patients with Diabetes Mellitus type 2 and Non-Alcoholic Fatty Liver Disease. The main question it aims to answer is: Is there a beneficial effect regarding liver steatosis in patients receiving either of these 2 medications and which is more effective? Patients will undergo shearwave elastography, magnetic resonance imaging, and ultrasound. Furthermore, calculation of the Fatty Liver Index (FLI), the Fibrosis-4 Index (FIB-4), as well as the Aspartate Aminotransferase to Platelet ratio Index (APRI) and the NAFLD Fibrosis Score (NFS) will be performed. Researchers will compare 3 groups: Group 1 will receive oral Empagliflozin, as add-on to their previous treatment regimen, for 52 weeks. Group 2 will receive subcutaneous Dulaglutide, as add-on to their previous treatment regimen, for 52 weeks. Group 3 will receive other optimal antidiabetic treatment (apart from agents of the GLP1-ras or SGLT2-is families) for 52 weeks.

NCT ID: NCT05202886 Recruiting - Brain Death Clinical Trials

"LiverColor": Machine Learning in Liver Photographs

Start date: June 30, 2018
Phase: N/A
Study type: Interventional

The main goal of this project is to create a machine learning model in order to quantify liver steatosis in liver donor faster, more objective and reliable than histological analysis and surgeons point-of-view.

NCT ID: NCT04895943 Active, not recruiting - Obesity Clinical Trials

Bariatric Endoscopy and NAFLD

Start date: April 29, 2021
Phase:
Study type: Observational

Find out how bariatric endoscopy will influence the clinical course of non-alcoholic fatty liver disease.

NCT ID: NCT04669470 Recruiting - Obesity Clinical Trials

Bariatric Endoscopy and NAFLD

Start date: October 1, 2020
Phase: N/A
Study type: Interventional

Find out how bariatric endocopy will influence clinical course of non alcoholic fatty liver disease.

NCT ID: NCT04561804 Completed - Weight Loss Clinical Trials

NAFLD and Liver Fibrosis in Obese Adolescents

NAFLD
Start date: December 1, 2018
Phase:
Study type: Observational [Patient Registry]

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease resulting from excessive fat accumulation in the liver. Due to its close association with obesity, it has become the most common liver disease in children in the United States. NAFLD can result in progressive fibrosis and lead to end-stage liver disease. Best practices in management of pediatric NAFLD are not clearly defined. Our aim is to clarify the natural history of NAFLD in obese children after weight loss surgery compare to lifestyle intervention. Our secondary aim is to investigate the added value of elastography for the screening and diagnosis of NASH with fibrosis.

NCT ID: NCT04284371 Terminated - Obesity, Childhood Clinical Trials

The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric Patients

Start date: February 10, 2016
Phase:
Study type: Observational

The prevalence of liver steatosis, steatohepatitis, fibrosis, and hemosiderosis in overweight and obese US Military dependent pediatric patients using MR Elastography and Quantitative MRI

NCT ID: NCT04012021 Recruiting - Pancreatic Cancer Clinical Trials

EXplanted LIver and Ex-vivo Pancreatic Specimen Evaluation by 7 TESLA MRI

EXLIPSE
Start date: May 24, 2019
Phase: N/A
Study type: Interventional

Aim of this study is to evaluate the correlation between the characteristics detected by the 7T MRI equipment and the histological composition of native explanted livers (group A), liver graft excluded for donation (group B) and surgical specimens of primary pancreatic tumour, which underwent pancreaticoduodenectomy (group C).

NCT ID: NCT03957070 Completed - Liver Fibrosis Clinical Trials

The Sonic Incytes Liver Incyte System, Assessment of Liver Fibrosis and Steatosis

Start date: February 1, 2019
Phase: N/A
Study type: Interventional

Evaluate the feasibility of the Liver Incyte system for liver elasticity measurement in healthy volunteers and patients with liver fibrosis. To evaluate the discriminatory ability of elasticity measurements generated by Liver Incyte for healthy volunteers versus patients with liver fibrosis in comparison to FibroScan measurements.